Table 2.
Drug loading and entrapment efficiency of RLPMs
| Group | Rifapentine
|
Linezolid
|
Particle size (μm) | ||
|---|---|---|---|---|---|
| DL (%) | EE (%) | DL (%) | EE (%) | ||
| 1 | – | – | – | – | 22.54±1.57 |
| 2 | 10.22±0.26 | 61.32±1.58 | 3.85±0.10 | 23.10±0.59 | 23.65±2.67 |
| 3 | 14.89±0.28 | 59.56±1.10 | 4.38±0.06 | 17.52±0.22 | 25.38±1.91 |
| 4 | 19.68±0.87 | 47.23±2.08 | 7.21±0.18 | 17.30±0.43 | 28.86±2.19 |
| 5 | 19.90±0.97 | 47.76±2.33 | 7.38±0.31 | 17.71±0.74 | 48.56±3.46 |
| 6 | 16.08±0.27 | 38.59±0.65 | 6.86±0.45 | 16.46±1.09 | 21.09±1.25 |
| 7 | 14.44±0.47 | 57.76±1.88 | 8.88±0.28 | 15.22±0.48 | 26.65±1.05 |
| 8 | 18.51±0.26 | 55.53±0.78a,b | 8.42±0.24a,b | 16.87±0.47 | 27.38±1.28 |
Notes: All values represent the mean ± standard deviation values (n=3).
a
Indicates that the differences between Groups 5 and 8 with Group 4 were significant (P<0.05),
b
indicates that the differences between Groups 4 and 8 with Group 5 were significant (P<0.05). Groups 1–8 represent different fabrication conditions of microspheres. Each group has different a mass ratio of rifapentine and linezolid, stirring rate. and drug-to-polymer ratio of miscrospheres.
Abbreviations: RLPMs, rifapentine-linezolid-loaded poly(lactic acid-co-glycolic acid) microspheres; DL, drug loading; EE, entrapment efficiency.